While a direct inhibitor of DDR kinases has yet to show clinical promise for treatment of AML, targeting multiple aspects of the DDR using HDAC inhibitors in combination with azacytidine could potentially be added to the armamentarium of AML treatment. The gene discussed is HDAC9; the disease is acute myeloid leukemia.